Caris Life Sciences
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Caris Life Sciences
Less than two year after going public by a SPAC merger, Gemini will reverse merge with hematology-focused Disc. Bristol Myers Squibb and GentiBio will join forces on Treg development for inflammatory bowel disorders.
As part of In Vivo’s Rising Leaders series, Versameb CEO Klaas Zuideveld discusses the next-generation RNA company’s technology and target indications. He also shares more about his career journey, lessons learned, and gives insight into the contrasting business cultures within big pharma and biotech.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
- Services sold to health care facilities
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Artificial Intelligence
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Caris Life Sciences®
- Pharmatech, Inc.